

## **EISAI TO PRESENT LATEST CLINICAL DATA ON HALAVEN® (ERIBULIN) AND LENVATINIB AT 39TH ESMO CONGRESS**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting the latest clinical data on Halaven® (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, "Halaven") and lenvatinib mesylate (generic name; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib") will be presented during the 39th European Society for Medical Oncology (ESMO) Congress 2014, taking place in Madrid, Spain, from September 26 - 30.

For eribulin, three abstract poster presentations including a quality of life analysis of a Phase III study on metastatic breast cancer (Study 301) are to be presented at the meeting. In June this year, Halaven was approved in Europe for an additional indication of locally advanced or metastatic breast cancer which has progressed after at least one chemotherapeutic regimen for advanced disease (prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments).

For lenvatinib, an oral presentation highlighting an analysis of serum biomarker and tumor gene mutation associated with clinical outcomes of a Phase III study on radioiodine-refractory

Halaven (Eribulin)  Abstract No: 6906	HRQOL and disease symptoms in patients with locally advanced or metastatic breast cancer treated with eribulin or capecitabine in a post anthracycline and taxane setting.  <b>Poster Presentation</b>   September 27 (Sat), 12:45-13:45
Lenvatinib (E7080)  Abstract No:LBA30	Comprehensive analysis of serum biomarker and tumor gene mutation associated with clinical outcomes in the phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT).  <b>Oral Presentation</b>   September 27 (Sat), 10:20-10:35
Lenvatinib (E7080)  Abstract No: 4933	Phase II study of lenvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with all histologic subtypes of advanced thyroid cancer (differentiated, medullary and anaplastic).  <b>Poster Presentation</b>   September 28 (Sun), 13:00-14:00
Lenvatinib (E7080)  Abstract No: 6405	Subgroup analyses of a phase III, multicenter, double-blind, placebo controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer.  <b>Poster Presentation</b>   September 29 (Mon), 12:45-13:45
Lenvatinib (E7080)  Abstract No: 5582	Treatment-emergent hypertension and efficacy in the phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT).  <b>Poster Presentation</b>   September 29 (Mon), 12:45-13:45
Lenvatinib (E7080)  Abstract No: 5658	Characterization of tumor size changes over time from the phase III Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid (SELECT).  <b>Poster Presentation</b>   September 29 (Mon), 12:45-13:45

Media Inquiries:

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120